Press release
CD155 Antibody Market is expected to reach USD 5.4 billion by 2034, growing at a 9.6%CAGR.
" As of 2024, the global CD155 antibody market is valued at approximately $2.1 billion, driven by the expanding application of immunotherapies and increasing research in cancer treatments. Projections indicate an impressive growth trajectory, with the market expected to reach around $5.4 billion by 2034. This corresponds to a robust Compound Annual Growth Rate (CAGR) of 9.6% during the forecast period from 2025 to 2034."Exactitude Consultancy., Ltd. released a research report titled "CD155 Antibody Market". This report covers the global CD155 Antibody market sales, sales volume, price, market share, ranking of major companies, etc., and provides a detailed analysis by region, country, product type, and application. It also forecasts the market size of automotive kick sensors based on market patterns from 2020 to 2034 and future market trends. Along with quantitative data, this study also provides qualitative analysis for companies to formulate growth strategies, evaluate the competitive environment, and analyze their market positions.
Moreover, the report provides a professional in-depth examination of the CD155 Antibody Market's current scenario, CAGR, gross margin, revenue, price, production growth rate, volume, value, market share, and growth are among the market data assessed and re-validation in the research. The report will also cover key agreements, collaborations, and global partnerships soon to change the dynamics of the market on a global scale. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, the scope of new product development in new markets, pricing strategies, innovation possibilities, and much more.
This report is also available in the following languages : Japanese (CD155抗体), Korean (CD155 항체), Chinese (CD155抗体), French (Anticorps CD155), German (CD155-Antikörper), and Italian (Anticorpo CD155), etc.
Get a Sample Copy of This Report at: https://exactitudeconsultancy.com/request-sample/66218
Updated Version 2025 is available our Sample Report May Includes the:
➤ 2025 Latest updated research report with Overview, Definition, TOC, updated Top market players
➤ 190+ Pages Research Report
➤ Provide Chapter-wise guidance on the Request
➤ Updated Research Report Includes a List of tables & figures
➤ Report Includes updated 2025 Top Market Players with their latest Business Strategy, Sales Volume, and Revenue Analysis
➤ Facts and Factors updated research methodology
The purpose of this market analysis is to estimate the size and growth potential of the market based on the kind of product, the application, the industry analysis, and the area. Also included is a comprehensive competitive analysis of the major competitors in the market, including their company profiles, critical insights about their product and business offerings, recent developments, and important market strategies.
CD155 Antibody Market Segments:
According to the report, the CD155 Antibody Market is segmented in the following ways which fulfill the market data needs of multiple stakeholders across the industry value chain -
The Leading Players involved in the global CD155 Antibody market are:
Bristol-Myers Squibb , Roche , Merck & Co. , Eli Lilly and Company , Johnson & Johnson , AbbVie , Amgen , Pfizer , AstraZeneca , Novartis , GSK (GlaxoSmithKline) , Sanofi , Takeda Pharmaceutical Company , Daiichi Sankyo , Regeneron Pharmaceuticals
Market segmentation:
By Product Type
Monoclonal Antibodies
Polyclonal Antibodies
By Application
Cancer Immunotherapy
Drug Development
Diagnostic Research
By End User
Pharmaceutical Companies
Biotechnology Firms
Academic and Research Institutions
By Technology
ELISA
Western Blotting
Flow Cytometry
By Distribution Channel
Direct Sales
Online Sales
Buy this report and Get Up to 20% Discount At: https://exactitudeconsultancy.com/reports/66218/cd155-antibody-market
Trends and Opportunities of the Global CD155 Antibody Market:
The global CD155 Antibody market has seen several trends in recent years, and understanding these trends is crucial to stay ahead of the competition. The global CD155 Antibody market also presents several opportunities for players in the market. The increasing demand for CD155 Antibody in various industries presents several growth opportunities for players in the market.
Regional Outlook:
The following section of the report offers valuable insights into different regions and the key players operating within each of them. To assess the growth of a specific region or country, economic, social, environmental, technological, and political factors have been carefully considered. The section also provides readers with revenue and sales data for each region and country, gathered through comprehensive research. This information is intended to assist readers in determining the potential value of an investment in a particular region.
› North America: USA, Canada, Mexico, etc.
› Asia-Pacific: China, Japan, Korea, India, and Southeast Asia
› The Middle East and Africa: Saudi Arabia, the UAE, Egypt, Turkey, Nigeria, and South Africa
› Europe: Germany, France, the UK, Russia, and Italy
› South America: Brazil, Argentina, Columbia, etc.
Research Methodology:
✅ Research Objectives: This section provides an overview of the research study's primary objectives, encompassing the research questions and hypotheses that will be addressed.
✅ Research Design: The following section presents the comprehensive outline of the research design, encompassing the selected approach for the study (quantitative, qualitative, or mixed-methods), the methodologies utilized for data collection (surveys, interviews, focus groups), and the sampling strategy employed (random sampling, stratified sampling).
✅ Data Collection: This section involves gathering information from primary and secondary sources. Primary sources included the use of survey questionnaires and interview guides, while secondary sources encompassed existing data from reputable publications and databases. Data collection procedures involved meticulous steps such as data cleaning, coding, and entry to ensure the accuracy and reliability of the collected data.
✅ Data Analysis: The data were analyzed using various methods including statistical tests, qualitative coding, and content analysis.
✅ Limitations: The study's limitations encompass potential biases, errors in data sources, and overall data constraints.
Highlights of the Report:
✔ For the period 2025-2034, accurate market size and compound annual growth rate (CAGR) predictions are provided.
✔ Exploration and in-depth evaluation of growth potential in major segments and geographical areas.
✔ Company profiles of the top players in the global CD155 Antibody Market are provided in detail.
✔ Comprehensive investigation of innovation and other market developments in the global CD155 Antibody Market.
✔ Industry value chain and supply chain analysis that is dependable.
✔ A thorough examination of the most significant growth drivers, limitations, obstacles, and future prospects is provided.
Following are Some of the Most Important Questions that are Answered in this Report:
➼ What are the most important market laws governing major sections of the CD155 Antibody Market?
➼ Which technological advancements are having the greatest influence on the anticipated growth of the worldwide market for CD155 Antibody Market?
➼ Who are the top worldwide businesses that are now controlling the majority of the CD155 Antibody Market?
➼ What kinds of primary business models do the primary companies in the market typically implement?
➼ What are the most important elements that will have an impact on the expansion of the CD155 Antibody Market around the world?
➼ How do the main companies in the environment of the global CD155 Antibody Market integrate important strategies?
➼ What are the present revenue contributions of the various product categories on the worldwide market for CD155 Antibody Market, and what are the changes that are expected to occur?
Reason to Buy
✔ Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the global CD155 Antibody Market.
✔ Highlights key business priorities in order to guide the companies to reform their business strategies and establish themselves in the wide geography.
✔ The key findings and recommendations highlight crucial progressive industry trends in the CD155 Antibody Market, thereby allowing players to develop effective long-term strategies in order to garner their market revenue.
✔ Develop/modify business expansion plans by using substantial growth offerings in developed and emerging markets.
✔ Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those restraining the growth to a certain extent.
✔ Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation, and industry verticals.
Request for a FREE sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/66218
Table of Content:
Chapter 1: CD155 Antibody Market Overview, Drivers, Restraints and Opportunities, Segmentation overview
Chapter 2: CD155 Antibody Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Consumption, By Applications, CD155 Antibody Market share (%) and Growth Rate by Applications
Chapter 6: Complete profiling and analysis of Manufacturers
Chapter 7: Marketing Strategy Analysis, Distributors/Traders
Continue....
Discover More: Visit Our Website For Additional Reports!
https://www.newschannelasia.com/article/738908229-wind-turbine-composites-material-market-growth-from-usd-14-89-billion-in-2023-to-usd-23-11-billion-by-2033-driven-by-a-4-49-cagr
https://smb.thesnaponline.com/article/Polymer-Foam-Market-is-Projected-to-Grow-at-a-CAGR-of-54percent-from-2024-to-2031-or-Exactitude-Consultancy?storyId=66ec2000cb9a7b2afab756f4
https://smb.bluegrasslive.com/article/Air-Brake-System-Market-at-a-CAGR-of-48percent-during-the-forecast-period-2024-2030-Exactitude-Consultancy?storyId=668a7d11137b83ff8f9eedb9
https://www.todayinmarcom.com/article/726843330-flavors-fragrances-market-is-projected-to-reach-usd-30-89-billion-by-2030-exactitude-consultancy
https://pr.timesofsandiego.com/article/Oxygen-Therapy-Equipment-Market-is-projected-to-reach-USD-775-billion-by-2030-or-Exactiude-Consultancy?storyId=669f8f36709b0518e4cfa55b
https://www.connecticutbusinessherald.com/article/730630031-3d-modeling-market-is-expected-to-be-valued-at-usd-13-32-billion-by-2033-exactitude-consultancy
https://smb.state-journal.com/article/Liquid-Crystal-Polymer-Market-is-expected-to-be-valued-at-USD-158-Billion-by-2033-or-Exactitude-Consultancy?storyId=66a8dc75709b0518e4d9ca21
http://www.telecomstoday.com/article/732453276-protective-gloves-market-is-expected-to-be-valued-at-usd-41-04-billion-by-2033-exactitude-consultancy
https://smb.natchezdemocrat.com/article/Electric-Vehicle-Adhesives-Market-is-expected-to-be-valued-at-USD-1705-billion-by-2033-or-Exactitude-Consultancy?storyId=66b4cb89ff399ea85e292337
https://smb.clemmonscourier.net/article/Smart-Glass-Market-is-expected-to-be-valued-at-USD-1635-billion-by-2033-or-Exactitude-Consultancy?storyId=66c47102de91e57068f447a7
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CD155 Antibody Market is expected to reach USD 5.4 billion by 2034, growing at a 9.6%CAGR. here
News-ID: 4054499 • Views: …
More Releases from Exactitude Consultancy

Relapsed/Refractory Acute Myeloid Leukemia Market is expected to reach USD 6.1 b …
Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. Despite advances in frontline therapies, relapse is common, and many patients develop refractory disease, leaving limited treatment options and poor survival outcomes. Relapsed/refractory AML (R/R AML) remains a major unmet clinical need.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71571
In recent years, however, the…

Retinoblastoma Market to Reach USD 1.2 Billion by 2034
Retinoblastoma is a rare pediatric eye cancer that originates in the retina and primarily affects children under five years of age. It accounts for around 3% of all childhood cancers but is the most common intraocular malignancy in children. With improved awareness, early screening, and advances in treatment, survival rates in developed nations exceed 90%. However, challenges remain in low- and middle-income countries where delayed diagnosis and limited access to…

Severe Toxicities in Lymphoma Market Projected to Reach USD 3.7 Billion by 2034
Lymphoma, a group of blood cancers affecting the lymphatic system, is broadly classified into Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). While survival outcomes have improved significantly with chemotherapy, radiotherapy, targeted agents, and immunotherapies, many patients experience severe toxicities as side effects of treatment. These toxicities - ranging from cytokine release syndrome (CRS) and neurotoxicity in CAR-T therapy to myelosuppression, infections, and organ toxicities from chemotherapy and immunomodulators - can…

Soft Tissue Neoplasms Market to Reach USD 6.0 Billion by 2034
Soft tissue neoplasms are abnormal growths arising from connective tissues, including muscles, fat, nerves, tendons, and blood vessels. While some are benign, malignant forms such as soft tissue sarcomas (STS) pose serious clinical challenges due to their aggressive nature, rarity, and diverse histological subtypes. Representing about 1% of all adult cancers, these neoplasms require a wide spectrum of treatments ranging from surgery and radiotherapy to chemotherapy and novel targeted therapies.
Download…
More Releases for CD155
PSMA Antibody Market to Reach $3.2 Billion by 2032 with a Projected 6% CAGR, Cov …
Psma Antibody market Overview:
The global Psma Antibody market size was valued at USD 3.2 USD Billion in 2032 and is poised to grow at a significant CAGR of 6% during the forecast period of 2024-2032. It also includes market size and projection estimations for each of the five major regions from 2024 to 2032. The research report includes historical data, trending features, and market growth estimates for the future.
Furthermore,…
TIGIT Antibodies: Targeting Immune Suppression in the Tumor Microenvironment
TIGIT antibodies are gaining recognition for their ability to target immune suppression in the tumor microenvironment, offering a novel approach to enhancing anti-tumor immunity. The tumor microenvironment is a complex network of cells, molecules, and structures that can significantly influence tumor progression and response to therapy. By targeting the TIGIT immune checkpoint, TIGIT antibodies can disrupt the immunosuppressive mechanisms within this environment and promote a more effective immune response against…
TIGIT Antibodies: A New Frontier in Immune Checkpoint Inhibition
TIGIT antibodies represent a new frontier in immune checkpoint inhibition, offering a novel approach to cancer immunotherapy. Immune checkpoints are regulatory pathways that maintain immune homeostasis and prevent autoimmunity, but tumors often exploit these checkpoints to evade immune surveillance. TIGIT (T cell immunoreceptor with Ig and ITIM domains) is one such checkpoint, and targeting it with antibodies has shown significant promise in enhancing anti-tumor immune responses.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
TIGIT is expressed on…
The Future of TIGIT Antibodies in Personalized Cancer Treatment
The future of TIGIT antibodies in personalized cancer treatment looks promising, with the potential to revolutionize the way we approach cancer therapy. Personalized medicine aims to tailor treatments based on individual patient characteristics, including genetic, molecular, and immune profiles. TIGIT antibodies, by targeting a specific immune checkpoint, offer a new avenue for customizing cancer treatment and improving patient outcomes.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
TIGIT, an inhibitory receptor expressed on T cells, NK cells, and…
TIGIT Antibodies: A New Frontier in Immune Checkpoint Inhibition
TIGIT antibodies represent a new frontier in immune checkpoint inhibition, offering a novel approach to cancer immunotherapy. Immune checkpoints are regulatory pathways that maintain immune homeostasis and prevent autoimmunity, but tumors often exploit these checkpoints to evade immune surveillance. TIGIT (T cell immunoreceptor with Ig and ITIM domains) is one such checkpoint, and targeting it with antibodies has shown significant promise in enhancing anti-tumor immune responses.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
TIGIT is expressed on…
Biomarkers for Predicting Response to TIGIT Antibody Therapy
Identifying biomarkers for predicting response to TIGIT antibody therapy is crucial for optimizing treatment outcomes and personalizing cancer therapy. Biomarkers can help select patients who are most likely to benefit from TIGIT blockade, thereby improving the efficacy and reducing unnecessary exposure to the therapy.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
One of the most promising biomarkers for TIGIT antibody therapy is the expression level of CD155, the primary ligand for TIGIT. High levels of CD155 expression…